Choose a folder
Spotlight on local publications: Malaysia
Dr Radhakrishna Sothiratnam presented baseline Malaysian DISCOVER data at the 9th Malaysian Endocrine and Metabolic Society Annual Congress in Kuala Lumpur, Malaysia on Monday 4 May.
Of the 14 DISCOVER sites in Malaysia, 92.9% were in urban areas, 28.6% were primary care centres, 28.6% were general/community hospitals and 7.1% were university/teaching hospitals. The Malaysian DISCOVER investigators were primary care physicians (64.3%) and endocrinology/diabetology specialists (35.7%). Baseline data were collected from 330 patients in Malaysia, 91.0% of whom received metformin monotherapy as first-line treatment and 72.5% of whom received a sulphonylurea with metformin as second-line treatment. Malaysian patients had worse glycaemic control at baseline than the global DISCOVER population (mean HbA1c level of 9.0% versus 8.3%). At baseline, 9.9% of these patients had macrovascular complications and 26.3% had microvascular complications. The most common microvascular and macrovascular complications were chronic kidney disease (present in 14.6% of patients) and coronary artery disease (present in 4.2% of patients). Overall, these results highlight poor glycaemic control and high levels of vascular complications among DISCOVER patients in Malaysia, which indicates a need for more intensive management of type 2 diabetes.
Please continue to submit new proposals for future local and global analyses via the DISCOVER publications portal. We hope to share more local publications on the DISCOVER study programme in the future, so please let us know if you would like to share the news of your presentations with the DISCOVER community.